TNF Pharmaceuticals, Inc. (NASDAQ:TNFA – Get Free Report)’s share price fell 4.5% during trading on Thursday . The stock traded as low as $3.80 and last traded at $3.84. 361,715 shares were traded during mid-day trading, a decline of 90% from the average session volume of 3,511,287 shares. The stock had previously closed at $4.02.
TNF Pharmaceuticals Stock Performance
The stock has a market capitalization of $7.09 million, a PE ratio of -0.02 and a beta of 2.04. The company’s fifty day simple moving average is $4.15 and its two-hundred day simple moving average is $4.28.
About TNF Pharmaceuticals
TNF Pharmaceuticals, Inc operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases.
Recommended Stories
- Five stocks we like better than TNF Pharmaceuticals
- The gold chart Wall Street is terrified of…
- Elon Musk already made me a “wealthy man”
- Unlocked: Elon Musk’s Next Big IPO
- 1,500 Banks Just Handed the Fed Your Bank Account
- Silver paying 20% dividend. Plus 68% share gains
Receive News & Ratings for TNF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TNF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
